KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Deferred Revenue: 2017-2025

Historic Current Deferred Revenue for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $20.8 million.

  • Aquestive Therapeutics' Current Deferred Revenue fell 2.62% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.8 million, marking a year-over-year decrease of 2.62%. This contributed to the annual value of $21.1 million for FY2024, which is 37.89% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Current Deferred Revenue is $20.8 million, which was down 1.29% from $21.0 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Current Deferred Revenue high stood at $37.8 million for Q1 2023, and its period low was $765,000 during Q4 2021.
  • Its 3-year average for Current Deferred Revenue is $27.8 million, with a median of $22.8 million in 2024.
  • In the last 5 years, Aquestive Therapeutics' Current Deferred Revenue spiked by 2,140.32% in 2023 and then slumped by 39.74% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Current Deferred Revenue (Quarterly) stood at $765,000 in 2021, then skyrocketed by 97.78% to $1.5 million in 2022, then spiked by 2,140.32% to $33.9 million in 2023, then plummeted by 37.89% to $21.1 million in 2024, then dropped by 2.62% to $20.8 million in 2025.
  • Its last three reported values are $20.8 million in Q3 2025, $21.0 million for Q2 2025, and $20.8 million during Q1 2025.